ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.10 USD
-0.09 (-4.11%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.11 +0.01 (0.48%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRQR 2.10 -0.09(-4.11%)
Will PRQR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Other News for PRQR
Is PRQR positioned for a breakdown? Non-ADX 1,2,3,4 Bearish shows up after sinking 4.11%
Crossed Above 200 Day Moving Average appears for PRQR after 6.31% move
PRQR rises 3.52% on September 18, leaving the technical picture intact
MACD Bearish Centerline Cross appears for PRQR after 0.25% move
Fell Below 200 Day Moving Average appears for PRQR after 9.36% move